Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Cushing’s syndrome due to interaction between ritonavir or cobicistat and corticosteroids: a case–control study in the French Pharmacovigilance Database

Abstract : OBJECTIVES: To explore the frequent interaction between antiretroviral-boosting agents and corticosteroids causing Cushing's syndrome (CS) in the French Pharmacovigilance Database (FPVD). METHODS: We conducted a retrospective case-control study describing CS recorded in the FPVD between 1996 and 2018. Case was defined as CS occurring in people living with HIV (PLWH) and control was defined as CS in uninfected individuals. Drug-drug interaction (DDI) was defined as an interaction between corticosteroids and CYP3A4 inhibitors. Data concerning the DDI, corticosteroids involved, route of administration and seriousness of the CS were described. RESULTS: Among the 139 instances of CS identified, 34/35 cases (97%) had DDIs (31 with ritonavir and 3 with cobicistat) and 7/104 controls (7%) had DDIs (6 with itraconazole and 1 with verapamil). The main corticosteroid involved was inhaled fluticasone (28/35, 80%) among the cases and oral prednisone (38/104, 37%) among the controls. More CS cases (30/35, 86%) than CS controls (62/104, 60%) were serious (OR = 4.0, 95% CI = 1.4-14.4; P = 0.007). CONCLUSIONS: Antiretroviral-boosting agents were responsible for one out of four iatrogenic CS cases in a French national database. Prescribers should be aware of the risk of potentially serious DDIs between antiretroviral-boosting agents and corticosteroids, including single-tablet regimens containing cobicistat.
Liste complète des métadonnées

https://hal.umontpellier.fr/hal-02569350
Contributeur : Nathalie Salvy-Cordoba <>
Soumis le : lundi 11 mai 2020 - 11:49:11
Dernière modification le : vendredi 15 mai 2020 - 12:22:09

Identifiants

Citation

Laure Peyro-Saint-Paul, Paul Besnier, Ludivine Demessine, Michel Biour, Dominique Hillaire-Buys, et al.. Cushing’s syndrome due to interaction between ritonavir or cobicistat and corticosteroids: a case–control study in the French Pharmacovigilance Database. Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), 2019, 74 (11), pp.3291-3294. ⟨10.1093/jac/dkz324⟩. ⟨hal-02569350⟩

Partager

Métriques

Consultations de la notice

14